vs
加拿大国家铁路（CP）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
加拿大国家铁路的季度营收约是瑞思迈的2.0倍（$2.8B vs $1.4B），加拿大国家铁路净利率更高（27.7% vs 27.6%，领先0.1%），瑞思迈同比增速更快（11.0% vs 1.3%），加拿大国家铁路自由现金流更多（$537.3M vs $311.2M），过去两年瑞思迈的营收复合增速更高（9.0% vs 5.6%）
加拿大国家铁路是加拿大一级货运铁路企业，总部位于魁北克省蒙特利尔市，业务覆盖加拿大全境及美国中西部、南部区域，是加拿大两大主力货运铁路运营商之一，与加拿大太平洋堪萨斯城铁路公司齐名。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
CP vs RMD — 直观对比
营收规模更大
CP
是对方的2.0倍
$1.4B
营收增速更快
RMD
高出9.7%
1.3%
净利率更高
CP
高出0.1%
27.6%
自由现金流更多
CP
多$226.1M
$311.2M
两年增速更快
RMD
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $1.4B |
| 净利润 | $786.2M | $392.6M |
| 毛利率 | — | 61.8% |
| 营业利润率 | 41.4% | 34.6% |
| 净利率 | 27.7% | 27.6% |
| 营收同比 | 1.3% | 11.0% |
| 净利润同比 | -10.3% | 13.9% |
| 每股收益（稀释后） | — | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRMD
| Q4 25 | $2.8B | $1.4B | ||
| Q3 25 | $2.7B | $1.3B | ||
| Q2 25 | $2.7B | $1.3B | ||
| Q1 25 | $2.8B | $1.3B | ||
| Q4 24 | $2.8B | $1.3B | ||
| Q3 24 | $2.6B | $1.2B | ||
| Q2 24 | $2.6B | $1.2B | ||
| Q1 24 | $2.5B | $1.2B |
净利润CPRMD
| Q4 25 | $786.2M | $392.6M | ||
| Q3 25 | $671.6M | $348.5M | ||
| Q2 25 | $900.8M | $379.7M | ||
| Q1 25 | $664.3M | $365.0M | ||
| Q4 24 | $876.7M | $344.6M | ||
| Q3 24 | $611.0M | $311.4M | ||
| Q2 24 | $660.6M | $292.2M | ||
| Q1 24 | $565.8M | $300.5M |
毛利率CPRMD
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | — | 58.6% | ||
| Q3 24 | — | 58.6% | ||
| Q2 24 | — | 58.5% | ||
| Q1 24 | — | 57.9% |
营业利润率CPRMD
| Q4 25 | 41.4% | 34.6% | ||
| Q3 25 | 36.8% | 33.4% | ||
| Q2 25 | 36.6% | 33.7% | ||
| Q1 25 | 35.0% | 33.0% | ||
| Q4 24 | 40.6% | 32.5% | ||
| Q3 24 | 34.3% | 31.6% | ||
| Q2 24 | 35.4% | 31.2% | ||
| Q1 24 | 32.9% | 31.3% |
净利率CPRMD
| Q4 25 | 27.7% | 27.6% | ||
| Q3 25 | 25.3% | 26.1% | ||
| Q2 25 | 33.6% | 28.2% | ||
| Q1 25 | 24.2% | 28.3% | ||
| Q4 24 | 31.2% | 26.9% | ||
| Q3 24 | 23.9% | 25.4% | ||
| Q2 24 | 25.3% | 23.9% | ||
| Q1 24 | 22.2% | 25.1% |
每股收益（稀释后）CPRMD
| Q4 25 | — | $2.68 | ||
| Q3 25 | — | $2.37 | ||
| Q2 25 | — | $2.58 | ||
| Q1 25 | — | $2.48 | ||
| Q4 24 | — | $2.34 | ||
| Q3 24 | — | $2.11 | ||
| Q2 24 | — | $1.97 | ||
| Q1 24 | — | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $134.3M | $1.4B |
| 总债务越低越好 | $14.6B | $403.9M |
| 股东权益账面价值 | $33.5B | $6.3B |
| 总资产 | $62.7B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.43× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资CPRMD
| Q4 25 | $134.3M | $1.4B | ||
| Q3 25 | $300.0M | $1.4B | ||
| Q2 25 | $583.3M | $1.2B | ||
| Q1 25 | $507.4M | $932.7M | ||
| Q4 24 | $539.5M | $521.9M | ||
| Q3 24 | $338.0M | $426.4M | ||
| Q2 24 | $406.6M | $238.4M | ||
| Q1 24 | $378.9M | $237.9M |
总债务CPRMD
| Q4 25 | $14.6B | $403.9M | ||
| Q3 25 | $15.8B | $408.7M | ||
| Q2 25 | $15.5B | $658.4M | ||
| Q1 25 | $15.4B | $663.1M | ||
| Q4 24 | $14.5B | $662.9M | ||
| Q3 24 | $13.7B | $667.6M | ||
| Q2 24 | $13.8B | $697.3M | ||
| Q1 24 | $13.7B | $997.0M |
股东权益CPRMD
| Q4 25 | $33.5B | $6.3B | ||
| Q3 25 | $33.4B | $6.1B | ||
| Q2 25 | $33.7B | $6.0B | ||
| Q1 25 | $35.2B | $5.5B | ||
| Q4 24 | $35.0B | $5.3B | ||
| Q3 24 | $32.2B | $5.2B | ||
| Q2 24 | $32.0B | $4.9B | ||
| Q1 24 | $31.3B | $4.6B |
总资产CPRMD
| Q4 25 | $62.7B | $8.5B | ||
| Q3 25 | $63.3B | $8.3B | ||
| Q2 25 | $62.2B | $8.2B | ||
| Q1 25 | $64.3B | $7.6B | ||
| Q4 24 | $64.1B | $7.1B | ||
| Q3 24 | $60.0B | $7.2B | ||
| Q2 24 | $60.4B | $6.9B | ||
| Q1 24 | $59.6B | $6.8B |
负债/权益比CPRMD
| Q4 25 | 0.43× | 0.06× | ||
| Q3 25 | 0.47× | 0.07× | ||
| Q2 25 | 0.46× | 0.11× | ||
| Q1 25 | 0.44× | 0.12× | ||
| Q4 24 | 0.41× | 0.13× | ||
| Q3 24 | 0.42× | 0.13× | ||
| Q2 24 | 0.43× | 0.14× | ||
| Q1 24 | 0.44× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $537.3M | $311.2M |
| 自由现金流率自由现金流/营收 | 18.9% | 21.9% |
| 资本支出强度资本支出/营收 | 20.2% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.42× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $1.6B | $1.8B |
8季度趋势，按日历期对齐
经营现金流CPRMD
| Q4 25 | $1.1B | $339.7M | ||
| Q3 25 | $930.0M | $457.3M | ||
| Q2 25 | $989.1M | $538.8M | ||
| Q1 25 | $843.9M | $578.7M | ||
| Q4 24 | $1.2B | $308.6M | ||
| Q3 24 | $928.6M | $325.5M | ||
| Q2 24 | $932.9M | $440.1M | ||
| Q1 24 | $741.0M | $402.0M |
自由现金流CPRMD
| Q4 25 | $537.3M | $311.2M | ||
| Q3 25 | $302.2M | $414.4M | ||
| Q2 25 | $446.8M | $508.2M | ||
| Q1 25 | $324.9M | $557.9M | ||
| Q4 24 | $702.3M | $288.0M | ||
| Q3 24 | $382.5M | $307.7M | ||
| Q2 24 | $343.1M | $415.2M | ||
| Q1 24 | $356.2M | $380.8M |
自由现金流率CPRMD
| Q4 25 | 18.9% | 21.9% | ||
| Q3 25 | 11.4% | 31.0% | ||
| Q2 25 | 16.7% | 37.7% | ||
| Q1 25 | 11.8% | 43.2% | ||
| Q4 24 | 25.0% | 22.5% | ||
| Q3 24 | 15.0% | 25.1% | ||
| Q2 24 | 13.1% | 33.9% | ||
| Q1 24 | 14.0% | 31.8% |
资本支出强度CPRMD
| Q4 25 | 20.2% | 2.0% | ||
| Q3 25 | 23.7% | 3.2% | ||
| Q2 25 | 20.2% | 2.3% | ||
| Q1 25 | 18.9% | 1.6% | ||
| Q4 24 | 19.3% | 1.6% | ||
| Q3 24 | 21.4% | 1.5% | ||
| Q2 24 | 22.6% | 2.0% | ||
| Q1 24 | 15.1% | 1.8% |
现金转化率CPRMD
| Q4 25 | 1.42× | 0.87× | ||
| Q3 25 | 1.38× | 1.31× | ||
| Q2 25 | 1.10× | 1.42× | ||
| Q1 25 | 1.27× | 1.59× | ||
| Q4 24 | 1.42× | 0.90× | ||
| Q3 24 | 1.52× | 1.05× | ||
| Q2 24 | 1.41× | 1.51× | ||
| Q1 24 | 1.31× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CP
暂无分部数据
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
